Severance Hospital
| Corea del Sud | Turchia | Austria | |
| Immunoterapia con Keytruda (Pembrolizumab) | da $5,200 | da $3,300 | da $15,000 |
Bookimed non aggiunge costi extra ai prezzi di Immunoterapia con Keytruda (Pembrolizumab). Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica per la tua Immunoterapia con Keytruda (Pembrolizumab) al tuo arrivo.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali in Immunoterapia con Keytruda (Pembrolizumab) e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di Immunoterapia con Keytruda (Pembrolizumab).
Giorno 1
Giorno 2
Giorno 3
Giorno 4-5
Giorno 6
Giorno 7
Settimane 2-4
Si prega di notare che l'esperienza di ogni paziente può variare e si consiglia di seguire sempre le indicazioni del proprio operatore sanitario.
Il medico è uno specialista leader nel trattamento del cancro al seno, con un'ampia formazione ed esperienza. Ha completato la sua formazione e tirocinio presso il Centro Medico dell'Università Yonsei in Corea del Sud e ha lavorato come chirurgo presso il Centro Tumori Yonsei.<\/p>
Dal 2011 al 2013, ha servito come professore consulente nel dipartimento di cancro al seno presso l'Università di Anderson negli Stati Uniti. La sua ricerca si concentra sul trattamento del cancro al seno utilizzando farmaci ormonali e chemioterapici.<\/p>
Il medico è membro dell'Associazione Medica Coreana, della Società Americana di Oncologia Clinica e dell'Associazione Americana per la Ricerca sul Cancro.<\/p>
Keytruda, una forma di terapia immunobasata, sfrutta il sistema immunitario dell'organismo per colpire e distruggere le cellule tumorali utilizzando anticorpi monoclonali.
Common side effects of Keytruda in Korea include dermatologic issues like rashes, endocrine disorders such as hypothyroidism, and gastrointestinal distress. Retrospective data from major Seoul centers indicates that pneumonitis and severe skin reactions like toxic epidermal necrolysis are critical risks requiring immediate monitoring.
Bookimed Expert Insight: While major centers like Severance Hospital serve millions, their specialization in multidisciplinary care is vital for immunotherapy. Analysis shows that Korean protocols emphasize early intervention for pneumonitis, as it remains the primary cause of severe complications in East Asian patients compared to Western datasets.
Patient Consensus: Patients report that fatigue and thyroid changes often emerge by the second cycle. Many advise tracking symptoms daily and avoiding spicy or fermented foods if gastrointestinal issues like diarrhea begin.
South Korea health insurance currently covers Keytruda for 118 indications across 13 cancer types. Key covered areas include lung cancer, melanoma, bladder cancer, Hodgkin lymphoma, and gastric cancer. Recent 2026 expansions added cervical, esophageal, biliary tract, and small intestine cancers to the national reimbursement framework.
Bookimed Expert Insight: While insurance significantly reduces costs, South Korean reimbursement logic is strictly biomarker-gated. Our data shows clinics like Severance Hospital use advanced digital imaging and EHRs to streamline these approvals. Patients with MSI-H solid tumors often secure coverage faster than those with site-specific indications. Always confirm your PD-L1 status before traveling to avoid unexpected out-of-pocket expenses.
Patient Consensus: Patients emphasize that biopsy-confirmed biomarkers are the only way to avoid high copays. While coverage lags behind the US, the 5% copayment for approved indications makes Korean oncology centers highly accessible.
Keytruda is approved for early-stage perioperative treatment in South Korea for non-small cell lung cancer, triple-negative breast cancer, and head and neck squamous cell carcinoma. The Ministry of Food and Drug Safety grants these approvals, though national insurance coverage often lags behind regulatory status for early-stage use.
Bookimed Expert Insight: While South Korean clinics like Severance Hospital hold Joint Commission International accreditation, a significant gap exists between drug approval and insurance reimbursement. International patients often access these early-stage treatments as non-reimbursed services, which costs $5,200 to $8,500 per cycle. This is still approximately 68% lower than the $21,500 average cost in the United States.
Patient Consensus: Patients report that while regulatory approval exists, accessing Keytruda for early-stage cancer requires navigating complex hospital-specific committees. Many recommend preparing international clinical trial data to support out-of-pocket treatment requests at major Seoul centers.
Keytruda is administered in South Korea as an intravenous infusion within specialized oncology units at JCI-accredited facilities. The typical 200mg dose takes 30 minutes, followed by 60 minutes of clinical monitoring. Protocol requires pre-infusion bloodwork and corticosteroids to prevent adverse reactions during the three-week cycle.
Bookimed Expert Insight: While major centers like Severance Hospital serve millions of patients, international departments offer a streamlined experience. You can often secure same-day consultations and infusions by using these dedicated wings. This bypasses the 2-hour wait times typically found in Korea's public cancer facilities.
Patient Consensus: Patients recommend bringing personal entertainment for the mandatory observation period. Many find the integration of supportive care, such as hydration protocols, helpful for managing fatigue.